Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
EndoChoice said that it filed for an initial public offering that could fetch as much as $115 million, scarcely 2 months after pulling down a $57 million funding round for its Fuse full-spectrum endoscope.
Alpharetta, Ga.-based EndoChoice said it plans to trade on the New York Stock Exchange under the “GI” symbol. J.P. Morgan and BofA Merrill Lynch are acting as joint book-runner, with William Blair and Stifel as co-managers for the offering, which hasn’t yet been priced, EndoChoice said. Read more
Johnson & Johnson’s LifeScan arm said it plans to conduct a 142-person clinical trial to see whether 1 of its OneTouch blood glucose meters works better for patients with a companion app or on its own.
Researchers are slated to look at patients using LifeScan’s OneTouch Verio Flex blood glucose meter along with the OneTouch Reveal app, versus patients only using the Verio Flex over 6 months. Read more
Smith & Nephew added a pair of software assets to its Syncera generic sales business, a so-called “repless” model for orthopedic devices.
The British healthcare giant said it acquired the Virtual Backtable and TrayTouch applications from S2 Interactive for an undisclosed amount. Read more